Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRIW) Income towards Parent Company (2020 - 2025)

Biofrontera has reported Income towards Parent Company over the past 6 years, most recently at $5.6 million for Q4 2025.

  • Quarterly results put Income towards Parent Company at $5.6 million for Q4 2025, up 504.01% from a year ago — trailing twelve months through Dec 2025 was -$10.5 million (up 40.67% YoY), and the annual figure for FY2025 was -$10.5 million, up 40.67%.
  • Income towards Parent Company for Q4 2025 was $5.6 million at Biofrontera, up from -$6.6 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for BFRIW hit a ceiling of $5.6 million in Q4 2025 and a floor of -$16.0 million in Q3 2021.
  • Median Income towards Parent Company over the past 5 years was -$3.9 million (2021), compared with a mean of -$4.3 million.
  • Biggest five-year swings in Income towards Parent Company: tumbled 7698.39% in 2021 and later soared 504.01% in 2025.
  • Biofrontera's Income towards Parent Company stood at -$14.5 million in 2021, then skyrocketed by 80.8% to -$2.8 million in 2022, then surged by 226.61% to $3.5 million in 2023, then plummeted by 139.59% to -$1.4 million in 2024, then soared by 504.01% to $5.6 million in 2025.
  • The last three reported values for Income towards Parent Company were $5.6 million (Q4 2025), -$6.6 million (Q3 2025), and -$5.3 million (Q2 2025) per Business Quant data.